Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/12941
DC FieldValueLanguage
dc.contributor.authorGrozdanova, Aleksandraen_US
dc.contributor.authorHalimi Vesaen_US
dc.contributor.authorZaheer-Ud-Din Babaren_US
dc.contributor.authorArmond Dacien_US
dc.contributor.authorKaterina Ancevska Netkovskaen_US
dc.contributor.authorLjubica Suturkovaen_US
dc.date.accessioned2021-05-31T12:21:17Z-
dc.date.available2021-05-31T12:21:17Z-
dc.date.issued2020-08-03-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/12941-
dc.language.isoenen_US
dc.publisherInt. J. Environ. Res. Public Healthen_US
dc.relation.ispartofInt. J. Environ. Res. Public Healthen_US
dc.subjectbiosimilars; clinical practice; interchangeability; extrapolation; pharmacovigilance; regulatory; knowledge; confidence; educationen_US
dc.titleClinical and Regulatory Concerns of Biosimilars: A Review of Literatureen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/ijerph17165800-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Pharmacy-
Appears in Collections:Faculty of Pharmacy: Journal Articles
Files in This Item:
File Опис SizeFormat 
ijerph-17-05800 (3).pdf476.13 kBAdobe PDFView/Open
Прикажи едноставен запис

Page view(s)

86
Last Week
1
Last month
checked on 20.7.2025

Download(s)

100
checked on 20.7.2025

Google ScholarTM

Проверете

Altmetric


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.